IBRX261030C00005500
IBRX Oct 30 2026 5.50 Call
optionOPRA
InactiveSep 25, 2026
3.03USD-9.009%(-0.30)1Vol1OI
Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
5.5
Expiration
Oct 30, 2026
DTE
10d
Moneyness
ITM
Intrinsic
$2.86
IBRX 5.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $4.27 | +55.27% | 2 | 1 |
| Oct 30, 2026 | 10d | $3.03 | -9.01% | 1 | 1 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $4.50 | -12.62% | 1 | 7,684 |
| Jan 21, 2028 | 458d | $5.21 | -12.14% | 2 | 3,514 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.